• COAG share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of COAG shares has increased $3.45 since the market last closed. This is a 7.57% rise.

  • Closed at $49.02.

    The stock has remained unchanged in after-hours trading.

Key terms

About COAG

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded in 2020 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $2.29B

    A market capitalization between $2 billion and $10 billion places COAG in the mid-capitalization category.

Key terms

Smart score

Latest COAG news

Nov 06, 2026 2:17am ET Wedbush Sticks to Their Buy Rating for Hemab Therapeutics Holdings, Inc. (COAG) by TipRanks Oct 16, 2026 6:30am ET Analysts Offer Insights on NA Companies: Cleanspark (CLSK), Hemab Therapeutics Holdings, Inc. (COAG) and Microsoft (MSFT) by TipRanks Oct 15, 2026 5:40am ET Hemab Therapeutics initiated with an Overweight at JPMorgan by TipRanks Oct 12, 2026 7:40am ET Hemab Therapeutics initiated with a Buy at Rodman & Renshaw by TipRanks Sep 17, 2026 8:05am ET Hemab Therapeutics doses first patient in HMB-003 trial by TipRanks Aug 17, 2026 5:43am ET Hemab Therapeutics price target raised to $64 from $55 at Wedbush by TipRanks Aug 12, 2026 9:55am ET Hemab Therapeutics Holdings, Inc. (COAG) Gets a Buy from Wedbush by TipRanks Aug 11, 2026 11:45am ET Hemab Therapeutics price target raised to $60 from $52 at H.C. Wainwright by TipRanks Aug 11, 2026 7:16am ET Hemab Therapeutics reports Q2 EPS (80c), consensus (82c) by TipRanks
Nov 04, 2026 9:05am ET Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition by GlobeNewswire Nov 03, 2026 7:00am ET Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026 by GlobeNewswire Sep 24, 2026 4:01pm ET Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert by GlobeNewswire Sep 17, 2026 8:00am ET Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding by GlobeNewswire Aug 11, 2026 7:00am ET Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update by GlobeNewswire Jul 14, 2026 7:45am ET Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress by GlobeNewswire Jul 12, 2026 6:28am ET Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress by GlobeNewswire Jun 26, 2026 9:00am ET Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress by GlobeNewswire May 27, 2026 8:00am ET Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference by GlobeNewswire May 21, 2026 7:00am ET Hemab Therapeutics Reports First Quarter 2026 Financial Results by GlobeNewswire May 04, 2026 4:01pm ET Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire Apr 30, 2026 6:55pm ET Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering by GlobeNewswire

COAG Financials

1-year income & revenue

  • COAG total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • COAG net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • COAG earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

COAG Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

COAG Competitors

$ Market capP/E ratio$ Price1d change52-week range
  • How competitors are chosen

    COAG's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $2.29B

    A market capitalization between $2 billion and $10 billion places COAG in the mid-capitalization category.

Key terms

Latest investing news